Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518168

— · E

d5d5cb76-9bda-5caf-a2c5-6fbeb278d93a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.610
  • G2M_CHECKPOINT+0.540
  • MYC_TARGETS_V1+0.490
  • MYC_TARGETS_V2+0.400
  • INTERFERON_ALPHA_RESPONSE+0.360
  • SPERMATOGENESIS+0.300
  • OXIDATIVE_PHOSPHORYLATION+0.240
  • DNA_REPAIR+0.220
  • MITOTIC_SPINDLE+0.180
  • MTORC1_SIGNALING+0.150

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
  • ANGIOGENESIS-0.490
  • TNFA_SIGNALING_VIA_NFKB-0.420
  • UV_RESPONSE_DN-0.420
  • TGF_BETA_SIGNALING-0.380
  • COAGULATION-0.340
  • HYPOXIA-0.340
  • KRAS_SIGNALING_UP-0.340
  • ANDROGEN_RESPONSE-0.320
  • PROTEIN_SECRETION-0.290

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1504282dd-4fef-4f70-a709-6a545d00a263
colon-landscapes@1
——0.918
2TCGA-22-5481-01A-31R-1949-07
lung-landscapes@6
—cohortMD10.912
3SRR8518141
breast-umap@18
—E0.895
4SRR8518323
breast-umap@18
—E0.894
520020093.Her2HRneg
breast-umap@18
—E0.888
6SRR8518219
breast-umap@18
—E0.888
7TCGA-A2-A0CW-01A-21R-A115-07
breast-umap@18
—B0.887
8fcfc55a0-35e6-4fae-a599-66af11ba856d
melanoma-umap@29
——0.885
9TCGA-58-A46M-01A-11R-A24H-07
lung-landscapes@6
—cohortSQ20.877
10TCGA-A2-A4S3-01A-21R-A266-07
breast-umap@18
—B0.874

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.610Inavolisib— uncovered
G2M_CHECKPOINT0.540Inavolisib— uncovered
MYC_TARGETS_V10.490Inavolisib— uncovered
MYC_TARGETS_V20.400Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.360Inavolisib— uncovered
SPERMATOGENESIS0.300Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.240Remibrutinib— uncovered
DNA_REPAIR0.220Idelalisib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
MTORC1_SIGNALING0.150Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.150Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.140Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
KRAS_SIGNALING_DN0.090Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.080Idelalisib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered
PEROXISOME0.050Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.040Inavolisib— uncovered